Ethyl bromo-difluroacetate

Ethyl bromo-difluroacetate is used as the intermediate of Gemcitabine.
Gemcitabine is a pyrimidine nucleotide analogue, which belongs to anti metabolic anticancer drugs. It can prevent the progress of DNA synthesis in a certain period, that is, S-phase. It has the characteristics of wide anticancer spectrum, unique mechanism of action, low toxicity, no cross resistance with other chemotherapeutic drugs and no superposition of toxicity. Today, gemcitabine has been approved for use in more than 90 countries, becoming the first-line drug for the treatment of non-small cell lung cancer and the "gold standard" for the treatment of pancreatic cancer.